Aelis Farma SA (AELIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aelis Farma SA (AELIS) has a cash flow conversion efficiency ratio of -0.635x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.88 Million ≈ $-4.54 Million USD) by net assets (€6.11 Million ≈ $7.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aelis Farma SA - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Aelis Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AELIS total debt and obligations for a breakdown of total debt and financial obligations.
Aelis Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aelis Farma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DATRIX S.P.A.
F:BW6
|
N/A |
|
Daesung Microbiological Labs. Co. Ltd
KQ:036480
|
-0.018x |
|
Mesiniaga Bhd
KLSE:5011
|
0.048x |
|
Bharat Road Network Limited
NSE:BRNL
|
-0.109x |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
-0.155x |
|
4Sight Holdings Ltd
JSE:4SI
|
0.083x |
|
Higher Way Electronic Co Ltd
TWO:3268
|
-0.040x |
|
Tecnisa S.A
SA:TCSA3
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Aelis Farma SA (2018–2024)
The table below shows the annual cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Aelis Farma SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.12 Million ≈ $11.83 Million |
€-11.83 Million ≈ $-13.83 Million |
-1.170x | -22.67% |
| 2023-12-31 | €13.20 Million ≈ $15.43 Million |
€-12.59 Million ≈ $-14.71 Million |
-0.953x | -44.57% |
| 2022-12-31 | €19.79 Million ≈ $23.14 Million |
€-13.05 Million ≈ $-15.26 Million |
-0.659x | -103.12% |
| 2021-12-31 | €898.00K ≈ $1.05 Million |
€18.97 Million ≈ $22.18 Million |
21.125x | +505.27% |
| 2020-12-31 | €-710.00K ≈ $-830.06K |
€-2.48 Million ≈ $-2.90 Million |
3.490x | +245.50% |
| 2019-12-31 | €1.20 Million ≈ $1.41 Million |
€-2.89 Million ≈ $-3.38 Million |
-2.399x | -61.24% |
| 2018-12-31 | €2.38 Million ≈ $2.79 Million |
€-3.55 Million ≈ $-4.15 Million |
-1.488x | -- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more